1703-61-3

Usage

Uses

Used in Pharmaceutical Industry:
4-oxocyclopentane-1,2-dicarboxylic acid is used as a precursor in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures, contributing to the development of new drugs.
Used in Agricultural Chemical Industry:
4-oxocyclopentane-1,2-dicarboxylic acid is used as a precursor in the synthesis of agricultural chemicals, enabling the creation of effective compounds for pest control and crop protection.
Used in Polymer and Plastics Production:
4-oxocyclopentane-1,2-dicarboxylic acid is used as a building block in the production of polymers and plastics, providing a key component for the development of new materials with specific properties.
Used in Drug Delivery Systems:
4-oxocyclopentane-1,2-dicarboxylic acid is researched for its potential application in drug delivery, where it may enhance the efficiency and targeting of therapeutic agents.
Used in Metal Coordination Chemistry:
4-oxocyclopentane-1,2-dicarboxylic acid is studied as a chelating agent in metal coordination chemistry, where it can bind to metal ions to form stable complexes, useful in various applications such as catalysis and environmental remediation.

InChI:InChI=1/C7H8O5/c8-3-1-4(6(9)10)5(2-3)7(11)12/h4-5H,1-2H2,(H,9,10)(H,11,12)

Upstream product

• 77-93-0 citric acid triethyl ester 
• 18852-51-2 sodium cyanoacetic acid ethyl ester 
• 64-17-5 ethanol 
• 105-53-3 diethyl malonate 
• 4534-68-3 1,2,3,4-butanetetracarboxylic acid 
• 4373-15-3 1,2,3,4-butanetetracarboxylic acid tetraethyl ester 
• 92334-74-2 trans(3,4)-3-Hydroxymethyl-4-(1',2'-dihydroxy-ethyl)-cyclopentanol-⁽¹⁾ 
• 1641-42-5 meso-butane-1,2,3,4-tetracarboxylic acid tetramethyl ester 
• 4534-68-3 (2S,3R)-1,2,3,4-butanetetracarboxylic acid 
• 6261-04-7 2,3,4-tris(ethoxycarbonyl)cyclopentanone 
• 67885-96-5 2.3.4-Trimethoxycarbonylcyclopentanon 
• 115794-30-4 (+)-(1S,2S)-dimethyl-4-oxocyclopentane 1,2-dicarboxylate 

Downstream Products

• 862174-60-5 (1R,4R,5R)-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylic acid 
• 1042695-87-3 methyl (1R,2R,4S)-2-[5-hexen-1-yl(methyl)carbamoyl]-4-[[2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-methyl-4-quinolinyl]oxy]cyclopentanecarboxylate 
• 35079-19-7 trans-(1R,2R)-1,2-Bis(methoxycarbonyl)-4-oxocyclopentane 
• 1042695-89-5 (1R,2R,4S)-1-benzyl 2-methyl 4-hydroxycyclopentane-1,2-dicarboxylate 
• 1333964-81-0 benzyl methyl (1R,2R,4R)-4-hydroxy-1,2-cyclopentanedicarboxylate 
• 6453-07-2 dimethyl 4-oxocyclopentane-1,2-dicarboxylate 
• 6453-07-2 (+/-)-trans-4-oxo-1,2-cyclopentanedicarboxylic acid bis(methyl ester) 
• 187528-23-0 (3aR,6aR)-Tetrahydro-cyclopenta[c]furan-5-one 
• 923604-56-2 ethyl (1R,2S)-2-ethenyl-1-({[(1R,2R,4R)-2-[hex-5-en-1-yl-(methyl)carbamoyl]-4-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)cyclopentyl]carbonyl}-amino)cyclopropanecarboxylate 
• 1333964-84-3 benzyl methyl (1R,2R,4S)-4-([2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-methyl-4-quinolinyl]oxy)-1,2-cyclopentanedicarboxylate 
• 1333964-95-6 benzyl methyl (1R,2R,4S)-4-[(4-nitro-benzoyl)oxy]-1,2-cyclopentanedicarboxylate 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(-)- ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis- (1R,2S)-(-)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(-)-ephedrine from the precipitated salt obtained in step (b).

PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV

The present invention relates to synthesis procedures and intermediates of a compound offormula: (XVII) and the salts thereof.

Novel antifungal β-amino acids: Synthesis and activity against Candida albicans

A series of novel β-amino acids has been synthesized and tested for their in vitro antifungal activity against Candida albicans. A steep SAR was observed. β-Amino acid 21 (BAY 10-8888/PLD-118) revealed the most favourable activity-tolerability profile and was selected for clinical studies as a novel antifungal for the oral treatment of yeast infections.

Efficient asymmetric synthesis of β-amino acid BAY 10-8888/PLD-118, a novel antifungal for the treatment of yeast infections

The β-amino acid BAY 10-8888/PLD-118 is currently being investigated in phase II clinical studies as a novel antifungal for the treatment of yeast infections. An efficient asymmetric synthesis of this compound is described. The key step employed a highly enantioselective, quinine-mediated alcoholysis of a mesoanhydride intermediate.

The Synthesis of Novel Trans-Oxabicyclo[3,3,0]octane Systems as Potential Inhibitors of HIV Protease

The novel trans-3-oxabicyclo[3,3.0]octan-7-one system has been prepared by intramolecular ring closure of the corresponding cyclopentane diol. Peralkylation and benzylidene substitution of the octanone has allowed the preparation of tetra-alkylated potential inhibitors of HIV protease. Weak activity against HIV protease (IC50's 70-100μM) was observed.